Keryx Biopharmaceuticals, Inc. is a biopharmaceutical firm focused on the development of medicines for people with renal disease. The company has market cap of $624.99 million. The Firm is engaged in the manufacture, development and commercialization of products for use in treating human diseases. It currently has negative earnings. The Company’s marketed product, Auryxia , which is an orally available, absorbable, iron medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
The stock of Eastern Co (NASDAQ:EML) hit a new 52-week high and has $25.56 target or 9.00% above today’s $23.45 share price. The 9 months bullish chart indicates low risk for the $155.01 million company. The 1-year high was reported on Apr, 5 by Barchart.com. If the $25.56 price target is reached, the company will be worth $13.95 million more. About 40,415 shares traded or 226.40% up from the average. Eastern Co (NASDAQ:EML) has risen 16.36% since August 29, 2016 and is uptrending. It has outperformed by 8.12% the S&P500.
Analysts await Keryx Biopharmaceuticals (NASDAQ:KERX) to report earnings on April, 27. They expect $-0.19 EPS, up 13.64% or $0.03 from last year’s $-0.22 per share. After $-0.32 actual EPS reported by Keryx Biopharmaceuticals for the previous quarter, Wall Street now forecasts -40.63% EPS growth.
Since January 1, 0001, it had 0 buys, and 13 selling transactions for $249,158 activity.
About 405,711 shares traded. Keryx Biopharmaceuticals (NASDAQ:KERX) has risen 33.33% since August 29, 2016 and is uptrending. It has outperformed by 25.09% the S&P500.
Knoll Capital Management Lp holds 2.06% of its portfolio in Keryx Biopharmaceuticals for 200,000 shares. Baupost Group Llc Ma owns 25.79 million shares or 1.97% of their US portfolio. Moreover, Abrams Capital Management L.P. has 1.23% invested in the company for 5.72 million shares. The California-based Old West Investment Management Llc has invested 0.75% in the stock. Rhenman & Partners Asset Management Ab, a Sweden-based fund reported 425,111 shares.
Ratings analysis reveals 40% of Keryx Biopharmaceuticals’s analysts are positive. Out of 15 Wall Street analysts rating Keryx Biopharmaceuticals, 6 give it “Buy”, 2 “Sell” rating, while 7 recommend “Hold”. The lowest target is $1.80 while the high is $18. The stock’s average target of $8.64 is 48.45% above today’s ($5.82) share price. KERX was included in 30 notes of analysts from July 23, 2015. Maxim Group maintained Keryx Biopharmaceuticals (NASDAQ:KERX) on Thursday, February 25 with “Buy” rating. Zacks upgraded Keryx Biopharmaceuticals (NASDAQ:KERX) on Friday, August 28 to “Sell” rating. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) has “Buy” rating given on Monday, August 10 by Roth Capital. Maxim Group maintained the shares of KERX in report on Tuesday, March 29 with “Buy” rating. The firm earned “Underweight” rating on Thursday, August 13 by Morgan Stanley. TH Capital downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) rating on Monday, August 10. TH Capital has “Buy” rating and $6.0 target. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) has “Mkt Perform” rating given on Tuesday, August 11 by FBR Capital. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, October 5. The firm has “Buy” rating given on Tuesday, August 2 by Ladenburg Thalmann. Raymond James upgraded Keryx Biopharmaceuticals (NASDAQ:KERX) on Friday, February 26 to “Outperform” rating.
The Eastern Company manufactures and sells industrial hardware, security products and metal products from over six United States activities and seven foreign subsidiaries. The company has market cap of $155.01 million. The Firm maintains over 13 physical locations. It has a 18.83 P/E ratio. It operates through three divisions: Industrial Hardware, Security Products and Metal Products.
